topotecan has been researched along with Angiogenesis, Pathologic in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 15 (55.56) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, HK; Lee, K; Xia, Y | 1 |
| Hsu, CW; Huang, R; Li, S; Sakamuru, S; Xia, M; Zou, C | 1 |
| Patel, KJ; Tannock, IF; Trédan, O | 1 |
| Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Davis, AN; Hansen, JM; Langley, RR; Lin, YG; Merritt, WM; Nick, AM; Pradeep, S; Previs, RA; Sood, AK | 1 |
| Bocci, G; Di Desidero, T; Kerbel, RS; Man, S; Xu, P | 1 |
| Battaglia, F; Bosco, MC; Delfino, S; Ottaviano, C; Puppo, M; Ribatti, D; Varesio, L | 1 |
| Balthasar, JP; Bernacki, RJ; Shah, DK; Shin, BS; Tóth, K; Veith, J | 1 |
| Anver, MR; Bonomi, CA; Borgel, SD; Carter, JP; Gehrs, B; Hollingshead, M; Kinders, RJ; Melillo, G; Parchment, R; Raffeld, M; Rapisarda, A; Shoemaker, RH; Uranchimeg, B | 1 |
| Borgel, SD; Burkett, S; Butcher, DO; Hollingshead, M; Kenney, S; Raffeld, M; Schrump, DS; Shoemaker, RH; Stockwin, LH; Stone, G; Vistica, DT | 1 |
| Chandra, J; Coleman, RL; Danes, CG; Gershenson, DM; Han, LY; Jaffe, RB; Kamat, AA; Kim, HS; Lin, YG; Mangala, LS; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL | 1 |
| Carroll, AR; Coleman, RL; Dumble, M; Jennings, N; Kamat, AA; Kumar, R; Lin, YG; Lu, C; Matsuo, K; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL; Zhang, S | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Jalota-Badhwar, A; Joshi, KS; Kumar, S; Manohar, SM; Padgaonkar, AA; Rathos, MJ; Sonawane, V | 1 |
| Bookman, MA | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Huang, J; Kandel, JJ; Kim, ES; Manley, CA; McCrudden, KW; Middlesworth, W; New, T; O'Toole, K; Soffer, SZ; Yamashiro, DJ | 1 |
| Bonomi, CA; Borgel, SD; Braunschweig, T; Carter, JP; Hewitt, SM; Hollingshead, M; Melillo, G; Rapisarda, A; Shoemaker, RH; Uranchimeg, B; Zalek, J | 1 |
| Garber, K | 1 |
| McGuire, WP | 1 |
| Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
| Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL | 1 |
| Huang, J; Kandel, JJ; Kim, E; Manley, C; Middlesworth, W; Moore, JT; O'Toole, K; Soffer, SZ; Stolar, C; Yamashiro, DJ; Yokoi, A | 1 |
| Huang, J; Kandel, J; Kim, E; Manley, C; Middlesworth, W; Moore, JT; O'Toole, K; Soffer, SZ; Stolar, C; Yamashiro, D; Yokoi, A | 1 |
| List, AF | 1 |
| Huang, J; Kandel, JJ; Kim, ES; Manley, C; McCrudden, KW; Middlesworth, W; O'toole, K; Soffer, SZ; Thosani, A; Yamashiro, DJ; Yokoi, A | 1 |
3 review(s) available for topotecan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Small Molecule Libraries | 2012 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
2 trial(s) available for topotecan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
22 other study(ies) available for topotecan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform.
Topics: Angiogenesis Inhibitors; Bortezomib; Cell Line, Transformed; Coculture Techniques; Docetaxel; Drug Evaluation, Preclinical; Endothelium, Vascular; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mesenchymal Stem Cells; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Telomerase; Topotecan | 2018 |
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Coronary Vessels; Doxorubicin; Female; Humans; Kidney; Liver; Mice; Mice, Nude; Mitoxantrone; Myocardium; Neoplasms; Neovascularization, Pathologic; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2013 |
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Topics: Administration, Metronomic; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2015 |
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Topotecan; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Chick Embryo; Deferoxamine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; Neuroblastoma; Promoter Regions, Genetic; Time Factors; Topotecan; Transcription, Genetic; Transcriptional Activation; Vascular Endothelial Growth Factor A | 2008 |
Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Computer Simulation; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Peritoneal Neoplasms; Tissue Distribution; Topotecan; Vascular Endothelial Growth Factor A | 2009 |
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Proliferation; DNA Damage; Drug Synergism; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Chromosomes, Human, Pair 17; Chromosomes, Human, X; Disease Models, Animal; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Sarcoma; Topotecan; Translocation, Genetic; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Topotecan; Vascular Endothelial Growth Factor A | 2009 |
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Kaplan-Meier Estimate; Mice; Models, Biological; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Pyridines; Pyrimidines; Signal Transduction; Topotecan; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ephrin-B2; Female; Fluorescein Angiography; Fluorescent Antibody Technique, Indirect; Humans; In Situ Hybridization; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proto-Oncogene Proteins c-sis; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Wilms Tumor | 2004 |
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; Topoisomerase I Inhibitors; Topotecan; Transcription Factors; Xenograft Model Antitumor Assays | 2004 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Investigational; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Nuclear Proteins; Phenylpropionates; Topotecan; Transcription Factors; Transplantation, Heterologous | 2005 |
Is it time for some new approaches for treating advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure | 2006 |
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine | 1999 |
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Disease Models, Animal; Endothelial Growth Factors; In Situ Nick-End Labeling; Injections, Intraperitoneal; Kidney Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Reference Values; Sensitivity and Specificity; Survival Rate; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wilms Tumor | 2001 |
Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
Topics: Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Mice; Mice, Nude; Neovascularization, Pathologic; Topotecan; Wilms Tumor | 2001 |
Topotecan is anti-angiogenic in experimental hepatoblastoma.
Topics: Angiogenesis Inhibitors; Animals; Female; Hepatoblastoma; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |